Malignant mesothelioma is a tough cancer caused by asbestos. It’s hard to treat because it grows quickly and is tough to beat. A recent study took a close look at a protein called calretinin. Scientists wanted to see if it could help predict how long someone might live with this cancer and how well they might respond to treatment.
A Possible Game-Changer in Mesothelioma Care
The study looked at 265 patients with this mesothelioma. They checked how much calretinin was in their blood and looked at the genes linked to how calretinin works. Scientists used tests to measure calretinin and found differences in genes among patients. Then they checked if these things were connected to how long patients lived or how well they responded to chemotherapy.
Higher calretinin levels lead to shorter times without the cancer growing and shorter overall survival. But when they looked at other patient factors, this link wasn’t as strong. But, certain differences in genes still seemed connected to how long patients lived, even after considering other factors.
Patients with high calretinin levels were more likely to see the cancer grow again after cisplatin treatment. Having a calretinin level higher than 0.89 ng/mL was linked to a lower chance of survival during treatment. This is even when considering other things about the patients. Also, one of the gene differences, MIR335 rs3807348, seemed to show that patients might respond better to treatment.
Predicting Mesothelioma Results
Calretinin, a protein marker, has been useful in finding malignant mesothelioma. And it helps tell mesothelioma apart from other conditions caused by asbestos. But until now, we didn’t know much about how it might predict how long someone might live with this cancer or how well they might respond to treatment.
This study shows that treating malignant mesothelioma is tricky. Regular treatments like chemotherapy, surgery, and radiation haven’t improved how long patients live. Learning about markers like calretinin could help make personalized treatments. This would give patients better chances.
This study shows that calretinin might help predict how someone with this cancer might do, opening new ways to make treatments better.
This research tells us how important calretinin is in this cancer. It’s not only for finding the cancer. It might also help predict how long someone might live with mesothelioma. And it should show how well they might respond to treatment. It tells us we need to study more about calretinin to make better and more personalized treatments for people with malignant mesothelioma.
Zupanc, Cita, Alenka Franko, Danijela Štrbac, Viljem Kovač, Vita Dolžan, and Katja Goričar. “Serum Calretinin and Genetic Variability as a Prognostic and Predictive Factor in Malignant Mesothelioma.” International Journal of Molecular Sciences 25, no. 1 (January 2024): 190. https://doi.org/10.3390/ijms25010190.